Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
- PMID: 15541308
- DOI: 10.1016/j.neuron.2004.10.023
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
Abstract
Parkinson's disease (PD; OMIM #168600) is the second most common neurodegenerative disorder in the Western world and presents as a progressive movement disorder. The hallmark pathological features of PD are loss of dopaminergic neurons from the substantia nigra and neuronal intracellular Lewy body inclusions. Parkinsonism is typically sporadic in nature; however, several rare familial forms are linked to genetic loci, and the identification of causal mutations has provided insight into the disease process. PARK8, identified in 2002 by Funayama and colleagues, appears to be a common cause of familial PD. We describe here the cloning of a novel gene that contains missense mutations segregating with PARK8-linked PD in five families from England and Spain. Because of the tremor observed in PD and because a number of the families are of Basque descent, we have named this protein dardarin, derived from the Basque word dardara, meaning tremor.
Comment in
-
Protein kinases linked to the pathogenesis of Parkinson's disease.Neuron. 2004 Nov 18;44(4):575-7. doi: 10.1016/j.neuron.2004.11.008. Neuron. 2004. PMID: 15541303
Similar articles
-
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.Brain. 2005 Dec;128(Pt 12):2786-96. doi: 10.1093/brain/awh667. Epub 2005 Nov 4. Brain. 2005. PMID: 16272164
-
Familial Parkinson's disease: clinical and genetic analysis of four Basque families.Ann Neurol. 2005 Mar;57(3):365-72. doi: 10.1002/ana.20391. Ann Neurol. 2005. PMID: 15732106
-
Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation.Stem Cell Res. 2023 Feb;66:102995. doi: 10.1016/j.scr.2022.102995. Epub 2022 Dec 9. Stem Cell Res. 2023. PMID: 36528012
-
[Clinical molecular genetics for PARK8 (LRRK2)].Brain Nerve. 2007 Aug;59(8):839-50. Brain Nerve. 2007. PMID: 17713120 Review. Japanese.
-
α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Neurotoxicology. 2011. PMID: 21238487 Free PMC article. Review.
Cited by
-
The dynamics of the mitochondrial organelle as a potential therapeutic target.J Cereb Blood Flow Metab. 2013 Jan;33(1):22-32. doi: 10.1038/jcbfm.2012.158. Epub 2012 Oct 24. J Cereb Blood Flow Metab. 2013. PMID: 23093069 Free PMC article. Review.
-
LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells.Molecules. 2020 Sep 9;25(18):4122. doi: 10.3390/molecules25184122. Molecules. 2020. PMID: 32916992 Free PMC article.
-
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18. ACS Chem Neurosci. 2012. PMID: 22860184 Free PMC article. Review.
-
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain.PLoS One. 2012;7(5):e36581. doi: 10.1371/journal.pone.0036581. Epub 2012 May 15. PLoS One. 2012. PMID: 22615783 Free PMC article.
-
The class II histone deacetylases as therapeutic targets for Parkinson's disease.Neuronal Signal. 2020 Jun 9;4(2):NS20200001. doi: 10.1042/NS20200001. eCollection 2020 Jun. Neuronal Signal. 2020. PMID: 32714601 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
